Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gentian Diagnostics ASOSL:GENT -0.51%78 3-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 78/100 and a GF Value™ of kr60.72 (Significantly Undervalued). Among 614 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 162866.29% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Gentian Diagnostics AS's current 3-Year Share Buyback Ratio was 0.00%.
The historical rank and industry rank for Gentian Diagnostics AS's 3-Year Share Buyback Ratio or its related term are showing as below:
During the past 11 years, Gentian Diagnostics AS's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -11.40%. And the median was -0.05%.
OSL:GENT's 3-Year Share Buyback Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -2.6 * Ranked among companies with meaningful 3-Year Share Buyback Ratio only.
Gentian Diagnostics AS (OSL:GENT) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Gentian Diagnostics AS 3-Year Share Buyback Ratio Related Terms
OSL:GENT vs ABT, SYK, MDT: 3-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's 3-Year Share Buyback Ratio falls into.
Gentian Diagnostics AS 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.00 mean?
Gentian Diagnostics AS (OSL:GENT) has a 3-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #999999 out of 614 companies in the Medical Devices & Instruments industry.
Is Gentian Diagnostics AS's 3-Year Share Buyback Ratio too high?
Gentian Diagnostics AS's current 3-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Gentian Diagnostics AS ranks #999999 out of 614 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Gentian Diagnostics AS has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's 3-Year Share Buyback Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #999999 out of 614 companies for 3-Year Share Buyback Ratio. This places Gentian Diagnostics AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current 3-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr60.72, compared to a current price of kr39.00 — trading 35.8% below its estimated fair value. The current 3-Year Share Buyback Ratio is 0.00. Gentian Diagnostics AS's overall GF Score™ is 78/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current 3-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr39.00 is trading 35.8% below its estimated GF Value™ of kr60.72.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
3-Year Share Buyback Ratio: 0.00
GF Value™: kr60.72 vs. price of kr39.00 (35.8% below fair value)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
78GF Score
Get the complete analysis for OSL:GENT
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
